NCT03190330View on ClinicalTrials.gov

A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

PHASE4CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

June 26, 2019

Primary Completion Date

May 3, 2023

Study Completion Date

May 3, 2023

Conditions
Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Mantle-Cell
Interventions
DRUG

Ibrutinib 420 mg

Ibrutinib capsule administered orally at a dose of 420 mg for CLL participants.

DRUG

Ibrutinib 560 mg

Ibrutinib capsule administered orally at a dose of 560 mg for MCL participants.

Trial Locations (10)

160012

Post Graduate Institute of Medical Education And Research PGIMER, Chandigarh

302017

Bhagwan Mahaveer Cancer Hospital & Research Centre, Jaipur

380013

Avron Hospitals Pvt. Ltd, Ahmedabad

411004

Deenanath Mangeshkar Hospital and Research Centre, Pune

411013

Noble Hospital Pvt Ltd, Pune

500034

Basavatarakam Indo-American Hospital, Hyderabad

560064

Cytecare Hospitals Pvt. Ltd, Karnataka

605008

Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry

700019

Apollo Multispeciality Hospital Ltd, Kolkata

700156

Tata Medical Center, Kolkata

Sponsors
All Listed Sponsors
lead

Johnson & Johnson Private Limited

INDUSTRY